Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Novo Nordisk Appealing Patent Ruling

January 20, 2011 7:27 am | News | Comments

Novo Nordisk announced that a US District Court judge ruled that one of its patents, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.


FDA Changing Medical Device Review Process

January 20, 2011 7:14 am | by Matthew Perrone | News | Comments

The Food and Drug Administration is laying out plans to update the 35-year-old system used to approve most medical devices, which has been subject to increasing criticism by public safety advocates.


Ardea Offering 2.5M More Shares

January 20, 2011 7:08 am | News | Comments

Ardea Biosciences Inc. said it is publicly offering 2.5 million common shares. The company did not provide financial details on the offering.


Perrigo in $540M Deal for Paddock

January 20, 2011 7:04 am | News | Comments

Over-the-counter drugmaker Perrigo Co. said it will buy generic drugmaker Paddock Laboratories Inc. for $540 million. Perrigo said Paddock has about $200 million in annual revenue.


Mylan Gets FDA Nod for HIV Treatments

January 20, 2011 7:00 am | News | Comments

Drug developer Mylan Inc. said that the Food and Drug Administration tentatively approved the company's pediatric HIV treatment.


Health Agencies Expediting Telaprevir Reviews

January 20, 2011 6:57 am | News | Comments

Vertex Pharmaceuticals Inc. said that regulators in the U.S. and Canada will speed their reviews of its drug candidate telaprevir, meaning the hepatitis C therapy could be approved months earlier than usual.


Allos Reports New Folotyn Data

January 20, 2011 6:55 am | News | Comments

Allos Therapeutics Inc. said its lymphoma drug Folotyn helped some patients who had no response to previous therapies. The results were based on a new analysis of a midstage clinical trial that ended in 2009.


Levomilnacipran Flunks Latest Trial

January 20, 2011 6:48 am | News | Comments

Forest Laboratories Inc. said its depression treatment levomilnacipran failed in a late-stage clinical trial, as the drug was no more effective than a placebo at treating depression.


Animal-free Albumin

January 19, 2011 7:21 am | Product Releases | Comments

AMSBIO has announced the launch of ecoHSA - an animal-free preparation of the human albumin gene produced in the seeds of Asian Rice. Commercial human albumin proteins extracted from plasma have multiple and invaluable uses in cell culture work.


HPLC Column

January 19, 2011 7:15 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced its Syncronis HPLC column range. This new range unerringly delivers consistent, predictable separations, from run to run and column to column.


CRI Worldwide Acquires Lifetree Clinical

January 19, 2011 7:12 am | News | Comments

CRI Worldwide, LLC has completed its acquisition of Lifetree Clinical Research, LLC, creating one of the nation's largest research organizations focusing on the conduct and design of early-stage, patient population clinical trials.


CureFAKtor Drug Receives Orphan Status

January 19, 2011 7:06 am | News | Comments

CureFAKtor Pharmaceuticals, LLC announced that its lead compound, CFAK-C4 , which is in development for the treatment of pancreatic cancer, has been granted orphan drug designation by the U.S. Food and Drug Administration.


Mutation Leading to Cancer Identified

January 19, 2011 6:58 am | News | Comments

Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation’s discovery in 2008. The hunt is now yielding fruit.


New Advance in RNA Nanotechnology

January 19, 2011 6:54 am | News | Comments

Scientists are reporting an advance in overcoming a major barrier to the use of the genetic material RNA in nanotechnology—the field that involves building machines thousands of times smaller than the width of a human hair and now is dominated by its cousin, DNA.


GSK And Prosensa Begin Phase 3 DMD Trial

January 19, 2011 6:41 am | News | Comments

GlaxoSmithKline and Prosensa announced that the first patient has commenced treatment in the Phase 3 clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy, who have a dystrophin gene mutation amenable to an exon 51 skip.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.